[go: up one dir, main page]

AR002946A1 - A SET FOR USE IN THE TREATMENT OR PREVENTION OF OSTEOPOROSIS IN MAMMALS ACCORDING TO A CYCLIC DIET. - Google Patents

A SET FOR USE IN THE TREATMENT OR PREVENTION OF OSTEOPOROSIS IN MAMMALS ACCORDING TO A CYCLIC DIET.

Info

Publication number
AR002946A1
AR002946A1 ARP950100438A AR10043895A AR002946A1 AR 002946 A1 AR002946 A1 AR 002946A1 AR P950100438 A ARP950100438 A AR P950100438A AR 10043895 A AR10043895 A AR 10043895A AR 002946 A1 AR002946 A1 AR 002946A1
Authority
AR
Argentina
Prior art keywords
osteoporosis
prevention
treatment
diet
cyclic
Prior art date
Application number
ARP950100438A
Other languages
Spanish (es)
Inventor
Martine Gazard
Olivier Gros
Jacques Girard
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of AR002946A1 publication Critical patent/AR002946A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se refiere a un conjunto para uso en un ciclo terapéutico el cual se basa en la administración secuencial de ácido tiludrónico o de una saly/o solvato del mismo y de calcio durante 28 a 31 días, para el tratamiento y/o la prevención de la osteoporosis. Dicho conjunto contiene: (a) 7 dosis deácido tiludrónico o de una sal aceptable farmacéuticamente y/o un solvato del mismo y (b) un suplemento nutritivo dividido en dosis que se administrarándurante los 21 a 24 días posteriores a (a).The invention relates to a set for use in a therapeutic cycle which is based on the sequential administration of tiludronic acid or a salt and / or solvate thereof and calcium for 28 to 31 days, for the treatment and / or prevention of osteoporosis. Said set contains: (a) 7 doses of tiludronic acid or a pharmaceutically acceptable salt and / or a solvate thereof and (b) a nutritional supplement divided into doses to be administered during the 21 to 24 days after (a).

ARP950100438A 1994-12-06 1995-12-05 A SET FOR USE IN THE TREATMENT OR PREVENTION OF OSTEOPOROSIS IN MAMMALS ACCORDING TO A CYCLIC DIET. AR002946A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9414630A FR2727629A1 (en) 1994-12-06 1994-12-06 OSTEOPOROSIS TREATMENT CYCLE KIT

Publications (1)

Publication Number Publication Date
AR002946A1 true AR002946A1 (en) 1998-05-27

Family

ID=9469504

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP950100438A AR002946A1 (en) 1994-12-06 1995-12-05 A SET FOR USE IN THE TREATMENT OR PREVENTION OF OSTEOPOROSIS IN MAMMALS ACCORDING TO A CYCLIC DIET.

Country Status (20)

Country Link
EP (1) EP0797444A1 (en)
JP (1) JPH10509729A (en)
KR (1) KR980700083A (en)
CN (1) CN1168634A (en)
AR (1) AR002946A1 (en)
AU (1) AU4307396A (en)
BR (1) BR9509961A (en)
CA (1) CA2207028A1 (en)
CZ (1) CZ175397A3 (en)
FI (1) FI972383L (en)
FR (1) FR2727629A1 (en)
HU (1) HUT77382A (en)
IL (1) IL116168A0 (en)
MA (1) MA23737A1 (en)
NO (1) NO972558L (en)
PL (1) PL320564A1 (en)
SK (1) SK68597A3 (en)
TR (1) TR199501530A1 (en)
WO (1) WO1996017616A1 (en)
ZA (1) ZA9510184B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6432932B1 (en) 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
US5994329A (en) * 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
RU2387451C2 (en) 2002-05-10 2010-04-27 Ф.Хоффманн-Ля Рош Аг Bisphosphonic acids intended for treatment and prevention of osteoporosis
EP1790347B1 (en) 2002-12-20 2014-12-24 F. Hoffmann-La Roche AG High dose ibandronate formulation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0381296B1 (en) * 1984-04-30 1994-11-30 THE PROCTER & GAMBLE COMPANY Kit for use in the treatment of osteoporosis
US4761406A (en) * 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
ATE161423T1 (en) * 1992-06-30 1998-01-15 Procter & Gamble Pharma USE OF PHOSPHINATES TO TREAT OSTEOPOROSIS
FR2694558B1 (en) * 1992-08-05 1994-10-28 Sanofi Elf Monohydrate of the disodium salt of 4-chlorophenylthiomethylene bisphosphonic acid, its preparation, the pharmaceutical compositions containing it.

Also Published As

Publication number Publication date
TR199501530A1 (en) 1996-10-21
NO972558L (en) 1997-08-05
FI972383A7 (en) 1997-06-05
CZ175397A3 (en) 1997-10-15
SK68597A3 (en) 1997-11-05
FI972383A0 (en) 1997-06-05
ZA9510184B (en) 1996-06-11
MA23737A1 (en) 1996-07-01
FR2727629A1 (en) 1996-06-07
WO1996017616A1 (en) 1996-06-13
NO972558D0 (en) 1997-06-05
MX9704105A (en) 1997-09-30
IL116168A0 (en) 1996-01-31
HUT77382A (en) 1998-04-28
PL320564A1 (en) 1997-10-13
CN1168634A (en) 1997-12-24
CA2207028A1 (en) 1996-06-13
JPH10509729A (en) 1998-09-22
FI972383L (en) 1997-06-05
KR980700083A (en) 1998-03-30
EP0797444A1 (en) 1997-10-01
FR2727629B1 (en) 1997-02-28
AU4307396A (en) 1996-06-26
BR9509961A (en) 1997-11-25

Similar Documents

Publication Publication Date Title
ATE211387T1 (en) ORAL 1ALPHA-HYDROXYPREVITAMIN D
ES2040232T3 (en) MEDICINAL PREPARATIONS FOR ORAL ADMINISTRATION CONTAINING A SINGLE DOSE OF 10 TO 240 MG OF DIHIDROPIRIDINA.
ES2172510T3 (en) NEW COMBINATION OF FORMOTEROL AND BUDESONIDA.
AR042262A2 (en) USE OF 8,9-DIHYDROESTRONE FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF ATEROSCLEROSIS
ES2162615T3 (en) METHOD TO TREAT OR PREVENT TYPE 1 DIABETES THROUGH ORAL INSULIN ADMINISTRATION.
CR6458A (en) VALDECOXIB COMPOSITIONS
ES2188782T3 (en) PHARMACEUTICAL FORMULATIONS CONTAINING DARIFENACINE.
FI940787A0 (en) Dosage form for short-term administration of the drug
AR020803A1 (en) A COMPOSITION THAT INCLUDES FEXOFENADINE OR A PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINE
MX9700081A (en) Tacrine pharmaceutical compositions.
ATE189400T1 (en) BONE GROWTH-PROMOTING COMPOSITION
NO306377B1 (en) Dosage form for delivery of a drug
AR035946A1 (en) PHARMACEUTICAL COMPOSITIONS TO USE IN THE TREATMENT OF DISORDERS IN WOMEN PERIMENOPAUSIC, MENOPAUSIC OR POSMENOPAUSIC, AND USES OF SUCH COMPOSITIONS FOR THE PREPARATION OF MEDICINES
CO5540323A2 (en) ORAL ADMINISTRATION OF HORMONE PARATIROIDES AND CALCITONINE
AR002946A1 (en) A SET FOR USE IN THE TREATMENT OR PREVENTION OF OSTEOPOROSIS IN MAMMALS ACCORDING TO A CYCLIC DIET.
DE3875611D1 (en) PHARMACEUTICAL COMPOSITIONS.
ES2042831T3 (en) PROCEDURE FOR PREPARING A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OSTEOPOROSIS.
ATE123416T1 (en) ORALLY ADMINISTERED PHARMACEUTICAL PRODUCT, IN PARTICULAR FOR IRON AND MAGNESIUM SUBSTITUTION THERAPY.
KR830008678A (en) Analgesic composition
KR890001558A (en) Zephyron and its pharmaceutically acceptable acid addition salts alleviate panic disorder
SE8304818L (en) MEDICINE WITH ANTICULAR, SPASMOLYTIC AND LOCAL ANESTIC EFFECTS
JPS6438027A (en) Remedy for cancer
MD1588F1 (en) Method of burn shock treatment
UA15281A (en) Method for treatment of chronic coronary heart disease
DK493887A (en) BUCCAL FORMULATION